Clinical Trial Update: A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial listing indicates that GNC-035 is being studied in relapsed or refractory non-Hodgkin lymphoma and other hematologic malignancies in Phase 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Non-hodgkin Lymphoma

Drugs mentioned

• GNC-035

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Non-hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING